Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Oct 22, 2024 6:35pm
366 Views
Post# 36277602

Looking beyond the share price

Looking beyond the share price

I know it's hard to do. Afterall, Most posting on here , bought to sell later at a profit.
I say most, as we know full well there are a few shorting.

Want to make some decent $$$ ?  

The day will come, when we wake up to a morning press release, That being a buyout or business partner for the MBc trial.
 

A few interesting things very recently.

1. The investors presentation, PDF has been updated, for October.
My recommendation, give it a resd.
The overall feel is that of strong confidence in the MOA.
The clinical details of the trials, very well explained.
Missing? Very obvious lack of mention of any potential business development.
Previously they had 2 slides talking directly about.business development initiatives.
For many years always a side note regarding licensing inside & outside of America.
Now? Not a peep.

2. The press release a few weeks ago, Was a very strong statement. Notably they in writing discussed the accelerated approval option.

If nothing else, take the time , read & understand the October presentation.

The business development?  

They must have a partner  to proceed with the MBc trial.
Why remove the licensing statements.? 


folks can speculate from here to the moon & back.
both positive & negative rationales.
Truth ..l,we will know when things are announced. Not before.
stay tuned.
BTW , I would enjoy reading some specific comments about the investor presentation.
afterall, this is a biotech development company, talking about their developments.
My opinion. Much of the value is in the early slides.
they explain in general what Pela is.
the later slides explain how it works.
as well as potential sales opportunities.


 

<< Previous
Bullboard Posts
Next >>